Johannes Josef Fels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johannes Josef Fels has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Traverso
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
4 shared publications Lennart Lykke
4 shared publications- Morten Revsgaard Frederiksen
Devices and Delivery Solutions, Novo Nordisk A/S, Hilleroed, Denmark
4 shared publications - Niclas Roxhed
Department of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden
4 shared publications - Robert Langer
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
4 shared publications Siddartha Tamang
Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
4 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in Molecular Metabolism
- Vol. 115
Differentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity
- 31 October 2026
- Published by Elsevier in Molecular Metabolism
- Vol. 115
Open AccessDifferentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity
- Open Access
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (6) , 1497-1504
Interaction between Paracetamol Glucuronide and a Glucose-Sensitive Insulin Molecule (NNC2215): Increased Risk of Hypoglycemia
NNC2215 is an insulin analog with glucose-sensitive properties on activation of the insulin receptor. In NNC2215, a glucoside and a macrocycle with strong affinity to glucose were conjugated to insulin. This introduced a switch that is open (activated) or closed (inactivated) at high or low glucose, respectively. The current study investigated the interaction between NNC2215 and paracetamol glucuronide (PaG), a major human metabolite of paracetamol. Interactions between PaG or d-glucose and NNC2215 were investigated using native mass spectrometry and insulin receptor binding studies in vitro. Interactions between PaG or l-glucose and NNC2215 were studied during glucose clamp conditions in domestic pigs. NNC2215 bound >10-fold stronger to PaG than to d-glucose in vitro. At a clinically relevant PaG concentration (70 μmol/L), the binding affinity of NNC2215 to the insulin receptor was increased, particularly at low glucose concentrations. In the clamp experiment, intravenous administration of 2.0 g PaG versus 0.3 g/kg l-glucose led to a similar glucodynamic effect. These data demonstrate a relevant interaction between PaG and NNC2215, potentially introducing hypoglycemia risk with NNC2215 versus nonglucose-sensitive insulin after paracetamol administration. When engineering a glucose-sensitive insulin, it should be considered whether molecules other than glucose can alter the insulin activity.
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (6) , 1497-1504
Open AccessInteraction between Paracetamol Glucuronide and a Glucose-Sensitive Insulin Molecule (NNC2215): Increased Risk of Hypoglycemia
NNC2215 is an insulin analog with glucose-sensitive properties on activation of the insulin receptor. In NNC2215, a glucoside and a macrocycle with strong affinity to glucose were conjugated to insulin. This introduced a switch that is open (activated) or closed (inactivated) at high or low glucose, respectively. The current study investigated the interaction between NNC2215 and paracetamol glucuronide (PaG), a major human metabolite of paracetamol. Interactions between PaG or d-glucose and NNC2215 were investigated using native mass spectrometry and insulin receptor binding studies in vitro. Interactions between PaG or l-glucose and NNC2215 were studied during glucose clamp conditions in domestic pigs. NNC2215 bound >10-fold stronger to PaG than to d-glucose in vitro. At a clinically relevant PaG concentration (70 μmol/L), the binding affinity of NNC2215 to the insulin receptor was increased, particularly at low glucose concentrations. In the clamp experiment, intravenous administration of 2.0 g PaG versus 0.3 g/kg l-glucose led to a similar glucodynamic effect. These data demonstrate a relevant interaction between PaG and NNC2215, potentially introducing hypoglycemia risk with NNC2215 versus nonglucose-sensitive insulin after paracetamol administration. When engineering a glucose-sensitive insulin, it should be considered whether molecules other than glucose can alter the insulin activity.
- Open Access
- 16 October 2024
- Published by Springer Nature in Nature
- Vol. 634 (8035) , 944-951
Glucose-sensitive insulin with attenuation of hypoglycaemia
The risk of inducing hypoglycaemia (low blood glucose) constitutes the main challenge associated with insulin therapy for diabetes1,2. Insulin doses must be adjusted to ensure that blood glucose values are within the normal range, but matching insulin doses to fluctuating glucose levels is difficult because even a slightly higher insulin dose than needed can lead to a hypoglycaemic incidence, which can be anything from uncomfortable to life-threatening. It has therefore been a long-standing goal to engineer a glucose-sensitive insulin that can auto-adjust its bioactivity in a reversible manner according to ambient glucose levels to ultimately achieve better glycaemic control while lowering the risk of hypoglycaemia3. Here we report the design and properties of NNC2215, an insulin conjugate with bioactivity that is reversibly responsive to a glucose range relevant for diabetes, as demonstrated in vitro and in vivo. NNC2215 was engineered by conjugating a glucose-binding macrocycle4 and a glucoside to insulin, thereby introducing a switch that can open and close in response to glucose and thereby equilibrate insulin between active and less-active conformations. The insulin receptor affinity for NNC2215 increased 3.2-fold when the glucose concentration was increased from 3 to 20 mM. In animal studies, the glucose-sensitive bioactivity of NNC2215 was demonstrated to lead to protection against hypoglycaemia while partially covering glucose excursions.
- 16 October 2024
- Published by Springer Nature in Nature
- Vol. 634 (8035) , 944-951
Open AccessGlucose-sensitive insulin with attenuation of hypoglycaemia
The risk of inducing hypoglycaemia (low blood glucose) constitutes the main challenge associated with insulin therapy for diabetes1,2. Insulin doses must be adjusted to ensure that blood glucose values are within the normal range, but matching insulin doses to fluctuating glucose levels is difficult because even a slightly higher insulin dose than needed can lead to a hypoglycaemic incidence, which can be anything from uncomfortable to life-threatening. It has therefore been a long-standing goal to engineer a glucose-sensitive insulin that can auto-adjust its bioactivity in a reversible manner according to ambient glucose levels to ultimately achieve better glycaemic control while lowering the risk of hypoglycaemia3. Here we report the design and properties of NNC2215, an insulin conjugate with bioactivity that is reversibly responsive to a glucose range relevant for diabetes, as demonstrated in vitro and in vivo. NNC2215 was engineered by conjugating a glucose-binding macrocycle4 and a glucoside to insulin, thereby introducing a switch that can open and close in response to glucose and thereby equilibrate insulin between active and less-active conformations. The insulin receptor affinity for NNC2215 increased 3.2-fold when the glucose concentration was increased from 3 to 20 mM. In animal studies, the glucose-sensitive bioactivity of NNC2215 was demonstrated to lead to protection against hypoglycaemia while partially covering glucose excursions.
- Open Access
- 9 May 2023
- Published by Springer Nature in Research Square
Glucose-sensitive insulin with attenuation of hypoglycaemia
The risk of inducing hypoglycaemia (low blood glucose) constitutes the main challenge associated with insulin therapy for diabetes. Insulin doses must be adjusted to ensure blood glucose values within normal range, but matching insulin doses to fluctuating glucose levels is difficult since even a slightly higher insulin dose than needed can lead to a hypoglycaemic incidence which can be anything from uncomfortable to life-threatening. It has thus been a long-standing goal to engineer a glucose-sensitive insulin that can auto-adjust its bioactivity in a reversible manner according to ambient glucose levels to ultimately achieve better glycaemic control while lowering the risk of hypoglycaemia. Here we report the design and properties of NNC2215, an insulin conjugate with bioactivity that is reversibly responsive to glucose over the physiological range as demonstrated in vitro and in vivo. NNC2215 was engineered by conjugating a glucose-binding macrocycle and a glucoside to insulin, thereby introducing a “switch” that can open and close in response to glucose and thereby equilibrate insulin between active and less active conformations. The insulin receptor affinity of NNC2215 increased 12-fold when glucose concentration was increased from 0 to 20 mM. In animal studies, the glucose-sensitive bioactivity of NNC2215 was demonstrated to lead to protection against hypoglycaemia while partially covering glucose excursions.
- 9 May 2023
- Published by Springer Nature in Research Square
Open AccessGlucose-sensitive insulin with attenuation of hypoglycaemia
The risk of inducing hypoglycaemia (low blood glucose) constitutes the main challenge associated with insulin therapy for diabetes. Insulin doses must be adjusted to ensure blood glucose values within normal range, but matching insulin doses to fluctuating glucose levels is difficult since even a slightly higher insulin dose than needed can lead to a hypoglycaemic incidence which can be anything from uncomfortable to life-threatening. It has thus been a long-standing goal to engineer a glucose-sensitive insulin that can auto-adjust its bioactivity in a reversible manner according to ambient glucose levels to ultimately achieve better glycaemic control while lowering the risk of hypoglycaemia. Here we report the design and properties of NNC2215, an insulin conjugate with bioactivity that is reversibly responsive to glucose over the physiological range as demonstrated in vitro and in vivo. NNC2215 was engineered by conjugating a glucose-binding macrocycle and a glucoside to insulin, thereby introducing a “switch” that can open and close in response to glucose and thereby equilibrate insulin between active and less active conformations. The insulin receptor affinity of NNC2215 increased 12-fold when glucose concentration was increased from 0 to 20 mM. In animal studies, the glucose-sensitive bioactivity of NNC2215 was demonstrated to lead to protection against hypoglycaemia while partially covering glucose excursions.
- 30 August 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (1) , 103-109
Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors
Oral administration provides a simple and non-invasive approach for drug delivery. However, due to poor absorption and swift enzymatic degradation in the gastrointestinal tract, a wide range of molecules must be parenterally injected to attain required doses and pharmacokinetics. Here we present an orally dosed liquid auto-injector capable of delivering up to 4-mg doses of a bioavailable drug with the rapid pharmacokinetics of an injection, reaching an absolute bioavailability of up to 80% and a maximum plasma drug concentration within 30 min after dosing. This approach improves dosing efficiencies and pharmacokinetics an order of magnitude over our previously designed injector capsules and up to two orders of magnitude over clinically available and preclinical chemical permeation enhancement technologies. We administered the capsules to swine for delivery of clinically relevant doses of four commonly injected medications, including adalimumab, a GLP-1 analog, recombinant human insulin and epinephrine. These multi-day dosing experiments and oral administration in awake animal models support the translational potential of the system.
- 30 August 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (1) , 103-109
Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors
Oral administration provides a simple and non-invasive approach for drug delivery. However, due to poor absorption and swift enzymatic degradation in the gastrointestinal tract, a wide range of molecules must be parenterally injected to attain required doses and pharmacokinetics. Here we present an orally dosed liquid auto-injector capable of delivering up to 4-mg doses of a bioavailable drug with the rapid pharmacokinetics of an injection, reaching an absolute bioavailability of up to 80% and a maximum plasma drug concentration within 30 min after dosing. This approach improves dosing efficiencies and pharmacokinetics an order of magnitude over our previously designed injector capsules and up to two orders of magnitude over clinically available and preclinical chemical permeation enhancement technologies. We administered the capsules to swine for delivery of clinically relevant doses of four commonly injected medications, including adalimumab, a GLP-1 analog, recombinant human insulin and epinephrine. These multi-day dosing experiments and oral administration in awake animal models support the translational potential of the system.
- Open Access
- 22 January 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (4) , eabe2620
A microneedle platform for buccal macromolecule delivery
Microneedles with high drug-loaded tips allow fast and painless delivery of biologics into the buccal mucosa.
- 22 January 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (4) , eabe2620
Open AccessA microneedle platform for buccal macromolecule delivery
Microneedles with high drug-loaded tips allow fast and painless delivery of biologics into the buccal mucosa.
- Open Access
- 11 February 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (4) , 1181
Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative
Somapacitan is a long-acting, once-weekly, albumin-binding growth hormone (GH) derivative. The reversible albumin-binding properties leads to prolonged circulation half-life. Here, we investigated and compared somapacitan with human GH on downstream receptor signaling in primary hepatocytes and hepatocellular models and using isothermal titration calorimetry to characterize receptor binding of somapacitan in the presence or absence of human serum albumin (HSA). With non-invasive fluorescence imaging we quantitatively visualize and compare the temporal distribution and examine the tissue-specific growth hormone receptor (GHR) activation at distribution sites. We found that signaling kinetics were slightly more rapid and intense for GH compared with somapacitan. Receptor binding isotherms were characterized by a high and a low affinity interaction site with or without HSA. Using in vivo optical imaging we found prolonged systemically biodistribution of somapacitan compared with GH, which correlated with plasma pharmacokinetics. Ex vivo mouse organ analysis revealed that the temporal fluorescent intensity in livers dosed with somapacitan was significantly increased compared with GH-dosed livers and correlated with the degree of downstream GHR activation. Finally, we show that fluorescent-labeled analogs distributed to the hypertrophic zone in the epiphysis of proximal tibia of hypophysectomized rats and that somapacitan and GH activate the GHR signaling in epiphyseal tissues.
- 11 February 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (4) , 1181
Open AccessTissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative
Somapacitan is a long-acting, once-weekly, albumin-binding growth hormone (GH) derivative. The reversible albumin-binding properties leads to prolonged circulation half-life. Here, we investigated and compared somapacitan with human GH on downstream receptor signaling in primary hepatocytes and hepatocellular models and using isothermal titration calorimetry to characterize receptor binding of somapacitan in the presence or absence of human serum albumin (HSA). With non-invasive fluorescence imaging we quantitatively visualize and compare the temporal distribution and examine the tissue-specific growth hormone receptor (GHR) activation at distribution sites. We found that signaling kinetics were slightly more rapid and intense for GH compared with somapacitan. Receptor binding isotherms were characterized by a high and a low affinity interaction site with or without HSA. Using in vivo optical imaging we found prolonged systemically biodistribution of somapacitan compared with GH, which correlated with plasma pharmacokinetics. Ex vivo mouse organ analysis revealed that the temporal fluorescent intensity in livers dosed with somapacitan was significantly increased compared with GH-dosed livers and correlated with the degree of downstream GHR activation. Finally, we show that fluorescent-labeled analogs distributed to the hypertrophic zone in the epiphysis of proximal tibia of hypophysectomized rats and that somapacitan and GH activate the GHR signaling in epiphyseal tissues.
- 7 October 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (10) , 1512-1518
A luminal unfolding microneedle injector for oral delivery of macromolecules
Insulin and other injectable biologic drugs have transformed the treatment of patients suffering from diabetes1,2, yet patients and healthcare providers often prefer to use and prescribe less effective orally dosed medications3,4,5. Compared with subcutaneously administered drugs, oral formulations create less patient discomfort4, show greater chemical stability at high temperatures6, and do not generate biohazardous needle waste7. An oral dosage form for biologic medications is ideal; however, macromolecule drugs are not readily absorbed into the bloodstream through the gastrointestinal tract8. We developed an ingestible capsule, termed the luminal unfolding microneedle injector, which allows for the oral delivery of biologic drugs by rapidly propelling dissolvable drug-loaded microneedles into intestinal tissue using a set of unfolding arms. During ex vivo human and in vivo swine studies, the device consistently delivered the microneedles to the tissue without causing complete thickness perforations. Using insulin as a model drug, we showed that, when actuated, the luminal unfolding microneedle injector provided a faster pharmacokinetic uptake profile and a systemic uptake >10% of that of a subcutaneous injection over a 4-h sampling period. With the ability to load a multitude of microneedle formulations, the device can serve as a platform to orally deliver therapeutic doses of macromolecule drugs.
- 7 October 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (10) , 1512-1518
A luminal unfolding microneedle injector for oral delivery of macromolecules
Insulin and other injectable biologic drugs have transformed the treatment of patients suffering from diabetes1,2, yet patients and healthcare providers often prefer to use and prescribe less effective orally dosed medications3,4,5. Compared with subcutaneously administered drugs, oral formulations create less patient discomfort4, show greater chemical stability at high temperatures6, and do not generate biohazardous needle waste7. An oral dosage form for biologic medications is ideal; however, macromolecule drugs are not readily absorbed into the bloodstream through the gastrointestinal tract8. We developed an ingestible capsule, termed the luminal unfolding microneedle injector, which allows for the oral delivery of biologic drugs by rapidly propelling dissolvable drug-loaded microneedles into intestinal tissue using a set of unfolding arms. During ex vivo human and in vivo swine studies, the device consistently delivered the microneedles to the tissue without causing complete thickness perforations. Using insulin as a model drug, we showed that, when actuated, the luminal unfolding microneedle injector provided a faster pharmacokinetic uptake profile and a systemic uptake >10% of that of a subcutaneous injection over a 4-h sampling period. With the ability to load a multitude of microneedle formulations, the device can serve as a platform to orally deliver therapeutic doses of macromolecule drugs.
- Open Access
- 7 June 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 44 (2) , 447-456
Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen Minipigs
Background/Objectives Cholecystokinin (CCK) is a regulator of appetite and energy intake in man. The aim of this study was to determine the effect of NN9056, a long-acting CCK-1 receptor-selective CCK analogue, on food intake and body weight (BW) in obese Göttingen Minipigs. Subjects/Methods Tolerability of NN9056 and acute effects on food intake, pancreas histology, amylase and lipase levels were assessed in lean domestic pigs in doses up to 100 nmol/kg (n = 3–4). Subsequently, obese Göttingen Minipigs were treated subcutaneously (s.c.) once daily for 13 weeks with vehicle, NN9056 low dose (regulated from 5 to 2 nmol/kg) or NN9056 high dose (10 nmol/kg) (n = 7–8). Food intake was measured daily and BW twice weekly. At the end of the treatment period, an intravenous glucose tolerance test (IVGTT) and a 24-h exposure profile was obtained. Data are mean ± SD. Results The acute studies in domestic pigs showed significant and dose-dependent effect of NN9056 on food intake, acceptable tolerability and no histopathological signs of pancreatitis. Sub-chronic treatment in obese Göttingen Minipigs was also well tolerated and accumulated food intake was significantly lower in both treated groups compared to vehicle, with no significant difference between the dose levels of NN9056 (41.8 ± 12.6, 51.5 ± 13.8 and 86.5 ± 19.5 kg in high-dose, low-dose and vehicle groups, respectively, p = 0.012 and p < 0.0001 for low and high dose vs. vehicle, respectively). Accordingly, there was a weight loss in both treated groups vs. a weight gain in the vehicle group (−7.2 ± 4.6%, −2.3 ± 3.2% and 12.3 ± 3.9% in the high-dose, low-dose and vehicle groups, respectively, p < 0.0001 for both vs. vehicle). IVGTT data were not significantly different between groups. Conclusion NN9056, a long-acting CCK-1 receptor-selective CCK analogue, significantly reduced food intake and BW in obese Göttingen Minipigs after once daily s.c. dosing for 13 weeks.
- 7 June 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 44 (2) , 447-456
Open AccessLong-acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen Minipigs
Background/Objectives Cholecystokinin (CCK) is a regulator of appetite and energy intake in man. The aim of this study was to determine the effect of NN9056, a long-acting CCK-1 receptor-selective CCK analogue, on food intake and body weight (BW) in obese Göttingen Minipigs. Subjects/Methods Tolerability of NN9056 and acute effects on food intake, pancreas histology, amylase and lipase levels were assessed in lean domestic pigs in doses up to 100 nmol/kg (n = 3–4). Subsequently, obese Göttingen Minipigs were treated subcutaneously (s.c.) once daily for 13 weeks with vehicle, NN9056 low dose (regulated from 5 to 2 nmol/kg) or NN9056 high dose (10 nmol/kg) (n = 7–8). Food intake was measured daily and BW twice weekly. At the end of the treatment period, an intravenous glucose tolerance test (IVGTT) and a 24-h exposure profile was obtained. Data are mean ± SD. Results The acute studies in domestic pigs showed significant and dose-dependent effect of NN9056 on food intake, acceptable tolerability and no histopathological signs of pancreatitis. Sub-chronic treatment in obese Göttingen Minipigs was also well tolerated and accumulated food intake was significantly lower in both treated groups compared to vehicle, with no significant difference between the dose levels of NN9056 (41.8 ± 12.6, 51.5 ± 13.8 and 86.5 ± 19.5 kg in high-dose, low-dose and vehicle groups, respectively, p = 0.012 and p < 0.0001 for low and high dose vs. vehicle, respectively). Accordingly, there was a weight loss in both treated groups vs. a weight gain in the vehicle group (−7.2 ± 4.6%, −2.3 ± 3.2% and 12.3 ± 3.9% in the high-dose, low-dose and vehicle groups, respectively, p < 0.0001 for both vs. vehicle). IVGTT data were not significantly different between groups. Conclusion NN9056, a long-acting CCK-1 receptor-selective CCK analogue, significantly reduced food intake and BW in obese Göttingen Minipigs after once daily s.c. dosing for 13 weeks.
- Top Cited PapersOpen Access
- 8 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 363 (6427) , 611-615
An ingestible self-orienting system for oral delivery of macromolecules
Delivering fragile drugs to the gut: Oral delivery is the simplest and least invasive way to deliver many pharmaceuticals, but many drugs and medications, including insulin, cannot survive passage through the stomach or the gastrointestinal tract. Abramson et al. developed an ingestible delivery vehicle that could self-reorient from any starting position so as to attach to the gastric wall. Encapsulation of a spring in a sugar casing allowed for triggered actuation for the delivery of biomolecules. The approach successfully provided active insulin delivery in pigs. Science , this issue p. 611
- 8 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 363 (6427) , 611-615
Top Cited PapersOpen AccessAn ingestible self-orienting system for oral delivery of macromolecules
Delivering fragile drugs to the gut: Oral delivery is the simplest and least invasive way to deliver many pharmaceuticals, but many drugs and medications, including insulin, cannot survive passage through the stomach or the gastrointestinal tract. Abramson et al. developed an ingestible delivery vehicle that could self-reorient from any starting position so as to attach to the gastric wall. Encapsulation of a spring in a sugar casing allowed for triggered actuation for the delivery of biomolecules. The approach successfully provided active insulin delivery in pigs. Science , this issue p. 611